Citius Pharmaceuticals, Inc. (NASDAQ: CTXR) has transitioned from a development-stage biotechnology company to a commercial-stage entity with the launch of LYMPHIR™, an FDA-approved targeted immunotherapy for cutaneous T-cell lymphoma (CTCL). This milestone not only provides the company with a revenue-generating asset but also underscores its strategic focus on addressing critical care indications with significant unmet medical needs.
LYMPHIR™, approved by the U.S. Food and Drug Administration in August 2024, is designed for adult patients with relapsed or refractory Stage I-III CTCL after at least one prior systemic therapy. The commercial launch in December 2025 has yielded $5.6 million in net product revenue during the first six months of fiscal 2026, with gross margins of approximately 80%. Payer coverage has reached nearly 100% of covered commercial lives, and 83% of targeted accounts have achieved formulary inclusion or are under active review. Beyond the U.S., Citius Oncology announced an initial shipment to Europe in April 2026, indicating potential for global expansion.
The company's late-stage pipeline includes Mino-Lok®, an antibiotic lock solution designed to salvage central venous catheters in patients with catheter-related bloodstream infections (CRBSIs) and central line-associated bloodstream infections (CLABSIs). These infections are particularly serious in cancer and hemodialysis patients. Mino-Lok® met the primary and secondary endpoints of its pivotal Phase 3 trial and has received Qualified Infectious Disease Product (QIDP) and Fast Track designations from the FDA. With no FDA-approved therapies currently indicated for catheter salvage, Mino-Lok® addresses a critical void, and investor materials estimate worldwide sales potential of approximately $1.8 billion.
Another promising candidate is Halo-Lido (CITI-002), a proprietary topical formulation combining halobetasol and lidocaine for the symptomatic treatment of hemorrhoids. Affecting approximately 10 million Americans annually, hemorrhoids currently have no FDA-approved prescription products, positioning Halo-Lido to become the first if approved. The company completed a Phase 2b study in 2023 and has since engaged with the FDA to determine the next steps.
Citius is also developing a stem cell platform using induced pluripotent stem cell-derived mesenchymal stem cells (i-MSCs) for acute respiratory distress syndrome (ARDS), including lung injury associated with sepsis. Interim results from a proof-of-concept sheep model showed improvements in oxygenation, systemic shock, pulmonary vascular injury, and bacterial clearance compared with controls, supporting further investigation.
The leadership team, including Co-Founder and CEO Leonard Mazur and Executive Vice Chairman Myron Holubiak, brings extensive pharmaceutical experience in development, commercialization, and business development. This expertise is critical as Citius navigates the complexities of bringing multiple products to market.
With LYMPHIR™ generating commercial revenue and Mino-Lok®, Halo-Lido, and the stem cell platform advancing through development, Citius Pharmaceuticals is positioned to capitalize on multiple near-term and long-term catalysts. The company's diversified portfolio targets areas of high unmet need, offering differentiated commercial opportunities that could drive substantial value for shareholders.
